{"version":"1.0","type":"link","title":"Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.","author_name":"Takami J 외","author_url":"https://prs-insight.online/author/Takami%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/117983","thumbnail_width":1200,"thumbnail_height":630}